Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NanoViricides
Ebola Global Health Emergency Needs a Broad-Spectrum Drug – NV-387 is a Strong Potential Candidate, Says NanoViricides
May 22, 2026
NanoViricides, Inc. Has Filed its Quarterly Report – NV-387 Advancing for Phase II
May 22, 2026
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
May 20, 2026
NanoViricides Presenting at NIBA’s 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 – Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
May 16, 2026
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres
February 2, 2026
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave – NV-387 is Effective Against H3N2
January 13, 2026